| IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data ...
IRVINE, Calif., Nov. 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (NASDAQ: IDMI) today announced the presentation of updated survival data from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). The trial was part of a National Cancer Institute (NCI) funded cooperative group study conducted by the Children's Oncology Group (COG) and the data is based on long-term follow up of patients originally treated in the Phase 3 trial. The results demonstrated that the addition of L-MTP-PE, formerly known as Junovan, to chemotherapy during treatment for osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults, achieved statistically superior Overall Survival (OS) rates. "The statistically significant survival findings of L-MTP-PE in combination with chemotherapy in this study are very encouraging, particularly when compared to the outcome of these patients for the last 20 years," said Dr.
Rain turns bus stand into lake
The association made a strong case for grant of conveyance allowance for all doctors, including those serving in clinical hospitals for indoor emergency service without any official vehicle and also demanded the free telephone facility for PCMS doctors. It further urged the government to enhance the special lump sum allowance to doctors in rural service to Rs.500 in place of the present rate of Rs 150 per month, as also pay academic allowance of Rs 500 per month to specialist doctors, resume the higher qualification allowance to all post-graduate (PG) doctors without any qualifying condition of cut-off date of January, 1996. .
Biogen auction running out of steam, some bidders walking away before ...
Tysabri was taken off the market in 2005 after three patients in clinical trials developed PML (progressive multifocal leukoencephalopathy), a rare, but fatal brain infection. Two of the three cases resulted in death. The investor also added that Biogen has been spending USD 800m plus in research and development and the plan is to spend USD 5bn over the next five years. He said clearly Biogen sees some value and excitement over some of the drugs in various clinical trial phases. The investor said that buyers will be evaluating three independent factors in making their decisions: one is the growth of Tysabri; second is the synergies a buyer will have with Biogen and third will be the view on the pipeline. At least two to three US parties are also thought to have dropped out of the process, and a third person familiar with the situation said that interest is waning across the board, both in Europe and the US.
The givers: Wausau-area residents thankful for others' help
"I am a 34-year-old, single parent of a 16-year-old boy and I've struggled for years," wrote Rebecca Wolf of Antigo. "Almost four years ago, I decided to try to get my bachelor's degree in criminal justice administration while working full time to support my son. Since I've started college, I have had numerous problems, including my house flooding. "Last year, in October, my mother died, and I had a rough stretch. I ended up failing a course and in order to go on, I needed to come up with $1,500. (They won't let you continue if you don't pay it all.) I scrimped and pinched pennies, and nearly drove myself crazy trying to get the money together to go back to school. An old friend showed up where I worked and as we were talking, he asked me how my schooling was going. When I told him that I was going to have to quit, he didn't say much.
|
